


PATENT COOPERATION TREATY

From the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:


GIDDINGS Peter John
SMITHKLINE BEECHAM
Corporate Intellectual Property
Two New Horizons Court
Brentford
Middlesex TW8 9EP
GRANDE BRETAGNE



PCT

WRITTEN OPINION

(PCT Rule 66)



Applicant's or agent's file reference FB/DM/BC45203		Date of mailing (day/month/year)	17.01.2000
REPLY DUE		within 3 month(s) from the above date of mailing	
International application No. PCT/EP99/01894	International filing date (day/month/year) 17/03/1999	Priority date (day/month/year) 20/03/1998	
International Patent Classification (IPC) or both national classification and IPC C12N15/57			
Applicant SMITHKLINE BEECHAM BIOLOGICALS S.A. et al.			


- This written opinion is the **first** drawn up by this International Preliminary Examining Authority.
- This opinion contains indications relating to the following items:
 - I ☒ Basis of the opinion
 - II ☐ Priority
 - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
 - IV ☐ Lack of unity of invention
 - V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
 - VI ☐ Certain document cited
 - VII ☐ Certain defects in the international application
 - VIII ☐ Certain observations on the international application
- The applicant is hereby **invited to reply** to this opinion.

When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also: For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.
- The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 20/07/2000.

Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer / Examiner Grosskopf, R Formalities officer (incl. extension of time limits) Schou, S Telephone No. +49 89 2399 2156
---	---



I. Basis of the opinion

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed"*).

Description, pages:

1-38 as originally filed

Claims, No.:

1-28 as originally filed

Drawings, sheets:

1/3-3/3 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. This opinion has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

- ☐ the entire international application,
- ☒ claims Nos. 14-18,20-25,28,

because:

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☒ the claims, or said claims Nos. 14-18,20-22,25,28 are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 23,24.

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims
Inventive step (IS)	Claims 1-13,19,26,27
Industrial applicability (IA)	Claims

2. Citations and explanations

see separate sheet

Ad item III and V:

In the present application a nucleotide sequence (EST) has been isolated by using a differential expression assay. For said sequence which has been arbitrarily denominated "CASB12" no function has been or could be determined. Therefore, said sequence must be considered as a "classical" EST sequence.

In view of the fact that no function has been determined, there is also no problem recognisable which is solved by said sequence (or even by sequences which have a certain degree of homology).

Therefore, the question whether said sequence fulfils the requirements of Article 33.3 (or 33.2), in principle, cannot be answered, respectively has to be denied. Thus, claims which relate to the precisely defined nucleotide sequences or proteins lack an inventive activity.

From a different point of view the isolation of said sequence is also obvious in view of e.g. D1 (EMBL database entry HS1237334; accession number AA436049; 1-JUNE-1997; Hillier et al.: 'WashU-NCI human EST project.' XP002110434) which discloses part of said sequence. The isolation of a larger part which "comprises" said sequence must be regarded as being devoid of an inventive activity.

Moreover, and again in view of the fact that no function could be determined, claims which relate to the (potential) use of said sequences must be considered as being totally speculative (vaccine claims and use claims).

The same, in principle, applies for the claims directed to the protein since a protein has not been prepared.

Moreover, claims which even try to broaden the scope are unclear, since, on the one hand, the skilled person has absolutely no hint in which region the 70% identity must be maintained.

On the other hand, a variation of the sequence without an aim (i.e. to retain "a" or the function (which?)) renders the claim meaningless.

No opinion at all is possible with respect to claims 23 and 24 since said claims could not even be searched.

**WRITTEN OPINION
SEPARATE SHEET**

International application No. PCT/EP99/01894

Finally, claims which relate to SEQ ID NOs 3 and 4 are not novel over e.g. D1 (Biochim. et Biophys. Acta (1998), vol. 1399, pages 225-228) since they do not form part of the priority document.



EPA/EPO/EB
D-80290 München
+49 89 2399-0
TX 523 656 epmu d
FAX +49 89 2399-4465

Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Generaldirektion 2

Directorate General 2

Direction Générale 2

Correspondence with the EPO on PCT Chapter II demands

In order to ensure that your PCT Chapter II demand is dealt with as promptly as possible you are requested to use the enclosed self-adhesive labels with any correspondence relating to the demand sent to the Munich Office.

One of these labels should be affixed to a prominent place in the upper part of the letter or form etc. which you are filing.